FDA Weighs Broader Testosterone Use for 5,000-Patient Group, May Drop Prostate Cancer Warning
Updated
Updated · health.yahoo.com · Aug 20
FDA Weighs Broader Testosterone Use for 5,000-Patient Group, May Drop Prostate Cancer Warning
3 articles · Updated · health.yahoo.com · Aug 20
Summary
December 2025 FDA advisers reviewed whether testosterone therapy should be expanded beyond disease-linked deficiency to men with idiopathic low testosterone, while also considering removal of prostate cancer warnings.
More than 5,000 men followed for nearly three years in the TRAVERSE trial showed testosterone improved libido and modestly lifted mood without raising heart attack, stroke or prostate cancer risk.
The same study still found higher rates of irregular heartbeat, lung-artery blood clots and unexpectedly bone fractures, leaving regulators to weigh benefits against remaining safety concerns.
Current U.S. approval is limited to men with low testosterone tied to a medical condition, and doctors often diagnose deficiency below 300 ng/dl across multiple tests.
Interest in broader use has surged as aging men seek energy, muscle and sexual-health gains, even though experts say evidence does not support testosterone as a general longevity or wellness booster.
Could popular weight loss therapies completely reverse low testosterone and eliminate the need for risky hormone treatments altogether?
Why is the military planning to screen soldiers for low testosterone when medical guidelines strongly warn against testing without clear clinical symptoms?
Are young men chasing social media hormone trends unknowingly destroying their future fertility and heart health for a temporary energy boost?